Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL

Journal of Patient-Reported Outcomes

Table 5 EPP-QoL domain scores with respect to peak toxicity severity from previous 60 days

	Peak toxicity severity	N	Mean	*Std. Deviation*	*95% Confidence Interval for Mean*
	Peak toxicity severity	N	Mean	*Std. Deviation*	*Lower Bound*	*Upper Bound*
EPP Symptoms	None	150	5.5	10.9	3.8	7.3
	Mild	109	24.6	19.8	20.9	28.4
	Moderate	67	39.5	25.7	33.2	45.8
	Severe	26	42.6	27.4	31.5	53.6
EPP Wellbeing	None	150	43.6	30.9	38.6	48.5
	Mild	109	44.6	33.1	38.4	50.9
	Moderate	67	43.3	31.7	35.6	51.0
	Severe	26	41.0	28.4	29.6	52.5

N.b. Data from only patient classified as Worst imaginable in terms of peak sensitivity is not shown